Compare Simon Property Group Inc (SPG) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Simon Property Group Inc vs Zoetis Inc — how do they compare? Simon Property Group Inc trades at $199.42 (market cap $64.59B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Simon Property Group Inc is far larger — about 2.1× Zoetis Inc's market cap, and Simon Property Group Inc pays the higher dividend (4.46%). Which is the better fit depends on your goals — on Pluang, investors hold Simon Property Group Inc for 99 Days and Zoetis Inc for 70 Days on average.
| SPG | ZTS | |
|---|---|---|
Market Cap | $64.59B | $30.20B |
Volume | 1,093,907 | 6,175,327 |
Sector | Real Estate | Health |
52-Week High | $236.70 | $147.53 |
52-Week Low | $173.35 | $69.09 |
Typical Hold Time | 99 Days | 70 Days |
Enterprise Value | $93.03B | $37.76B |
Dividend Yield | 4.46% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPG trades at $199.42, up 0.93% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $6.36B in 2025 and a net income margin of 66.57%, though Q2 2026 EPS missed expectations. Recent news highlights leasing demand strength and a new media network launch, while analyst consensus is a $222.90 price target with 42% buy ratings.
Outlook is mixed: fundamentals are robust with high profitability and dividend yield, but technical weakness and net cash outflows pose risks. Investors may find value in the discounted valuation relative to targets, though sensitivity to interest rates and debt maturities requires caution.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
